{
  "session_id": "scenario_8829_b6175847_1770580612",
  "steps": [
    {
      "step_number": 1,
      "new_information": "Patient presents with extreme fatigue, jaundice (yellow skin), and an elevated alanine aminotransferase (ALT).",
      "uncertainties": {
        "Acute viral hepatitis (A/B/C)": "high ALT and jaundice consistent",
        "Drug-induced liver injury (including acetaminophen)": "can present similarly and may be life-threatening",
        "Obstructive/cholestatic disease (e.g., choledocholithiasis, malignancy)": "causes jaundice but typically with cholestatic lab pattern",
        "Autoimmune hepatitis": "possible in young adults with marked transaminase elevation."
      },
      "reference_relevance": "The guideline experiences were helpful — they emphasize obtaining vital signs early and eliciting exposure history (medications, acetaminophen, travel, vaccination, IV drug use, sexual contacts) and ordering hepatitis serologies and acetaminophen level. These recommendations apply well to this case, though they do not yet resolve which etiology is most likely without history and testing.",
      "action": "REQUEST TEST: Vital Signs",
      "action_reason": "Obtaining temperature, blood pressure, heart rate, respiratory rate and oxygen saturation immediately assesses hemodynamic stability and presence of fever. Fever would raise likelihood of acute viral hepatitis or systemic infection; hypotension or tachycardia could indicate severe illness or potential acute liver failure requiring urgent care. Vital signs are a required early data point to safely guide further diagnostic choices (e.g., urgent acetaminophen level, hospital admission, or outpatient workup)."
    },
    {
      "step_number": 2,
      "new_information": "Vital signs: Temperature 37.9°C, BP 100/74 mmHg, HR 72 bpm, RR 14/min.",
      "uncertainties": {
        "Acute viral hepatitis (A/B/C)": "presents with fatigue and jaundice with marked ALT elevation",
        "Drug-induced liver injury/acetaminophen toxicity": "can cause very high ALT—needs med/acetaminophen level",
        "Autoimmune hepatitis": "subacute fatigue and jaundice, more common in younger females",
        "Biliary obstruction/cholestatic process": "less likely with isolated ALT elevation but consider if dark urine/pale stools or cholestatic labs present."
      },
      "reference_relevance": "Guidelines are helpful — they recommend early targeted history (age/sex, symptom onset, travel, vaccination), exposure history (medications, acetaminophen, alcohol, IV drug use, sexual exposures), and appropriate labs (hepatitis serologies, acetaminophen level, hepatic panel including bilirubin/ALP/INR). These are applicable to this case to prioritize tests and narrow differential.",
      "action": "ASK PATIENT: What is your age and sex? When did your symptoms (fatigue and yellowing of skin) begin? Do you have dark urine or pale stools? Have you taken any medications, acetaminophen, or herbal supplements recently? Do you drink alcohol (how much and how often)? Any history of IV drug use, tattoos/piercings, recent unprotected sex, blood transfusions, or recent travel? Have you received hepatitis vaccinations?",
      "action_reason": "These questions directly distinguish between viral hepatitis (travel/exposure/vaccination, sexual/IDU risk), drug-induced liver injury/acetaminophen toxicity (recent med/supplement or acetaminophen use), alcoholic hepatitis (alcohol history), autoimmune hepatitis (age/sex and autoimmune history), and obstructive cholestasis (dark urine/pale stools). Answers will guide targeted testing (hepatitis serologies, acetaminophen level, autoimmune markers, imaging) and prioritize next steps."
    },
    {
      "step_number": 3,
      "new_information": "Patient moved from Africa at age 18 and likely has not received hepatitis vaccinations (no records).",
      "uncertainties": {
        "Acute hepatitis B": "higher pretest probability due to origin from an endemic area, history of IV drug use, acute jaundice and elevated ALT",
        "Acute hepatitis A or E": "possible given origin/travel and potential exposure to contaminated food/water",
        "Drug/toxin-induced liver injury": "patient denies medications but undisclosed exposures remain possible",
        "Biliary obstruction/cholestatic disease": "less likely without dark urine/pale stools but needs exclusion with cholestatic labs."
      },
      "reference_relevance": "Past experiences strongly support obtaining hepatic panel and hepatitis serologies in similar presentations — helpful because HBsAg and IgM anti-HBc can confirm acute HBV; experiences note atypical viral load patterns can occur, so broad viral testing plus liver synthetic function (PT/INR, albumin) and acetaminophen level are needed to confirm diagnosis and assess severity.",
      "action": "REQUEST TEST: Hepatic panel (AST, ALT, total and direct bilirubin, alkaline phosphatase), albumin, PT/INR, CBC, serum acetaminophen level, and viral hepatitis serologies (HAV IgM, HBsAg, anti-HBc IgM, HBV DNA quantit, HBeAg, anti-HCV and HCV RNA, HEV IgM if available).",
      "action_reason": "These tests will (1) confirm the pattern of liver injury (hepatocellular vs cholestatic), (2) assess liver synthetic function and severity (PT/INR, albumin), (3) identify acute viral etiologies (HBV, HAV, HCV, HEV) given epidemiologic risk, and (4) rule out acetaminophen toxicity as a common cause of marked ALT elevation."
    },
    {
      "step_number": 4,
      "new_information": "HBsAg positive and IgM anti-HBc positive with ALT 2000 IU/L; albumin, PT/INR, bilirubin, CBC, and acetaminophen level normal.",
      "uncertainties": {
        "1) Acute hepatitis B": "most likely given HBsAg+ and IgM anti-HBc with very high ALT",
        "2) Hepatitis D co-infection/superinfection": "can occur in HBsAg+ patients and cause more severe disease",
        "3) Drug-induced liver injury (including occult acetaminophen or herbal supplements)": "less likely given normal acetaminophen level but not excluded",
        "4) Other viral hepatitis (HEV) or autoimmune hepatitis": "less likely but possible."
      },
      "reference_relevance": "Guidelines/examples support acute HBV diagnosis with HBsAg+ and IgM anti-HBc and recommend assessment of viral replication (HBV DNA, HBeAg) and testing for HDV in HBsAg+ patients; guidance is helpful to prioritize these tests.",
      "action": "REQUEST TEST: HBV DNA quantitative, HBeAg, anti-HBe, anti-HDV IgM/IgG and HDV RNA, and HEV IgM if available.",
      "action_reason": "HBV DNA and HBeAg quantify viral replication and help determine need for antiviral therapy and prognosis. Testing for HDV is essential in any HBsAg+ patient because HDV co-infection/superinfection can worsen liver injury. HEV testing is reasonable given travel history from an endemic region and to exclude other viral causes of marked transaminitis."
    },
    {
      "step_number": 5,
      "new_information": "HBV DNA quantitative reported as normal/undetectable (despite HBsAg positive and IgM anti-HBc positive).",
      "uncertainties": {
        "Acute hepatitis B infection": "HBsAg + IgM anti-HBc strongly supports acute HBV but undetectable HBV DNA is unexpected (possible low viremia, early infection, or assay sensitivity/technical issue)",
        "Drug- or toxin-induced liver injury (DILI)": "marked ALT could be from an unrecognized hepatotoxin despite patient denial",
        "Autoimmune hepatitis": "can present with marked transaminase elevation and needs exclusion."
      },
      "reference_relevance": "Guidelines/experiences were helpful: they support acute HBV given serology and recommend repeating HBV DNA with a sensitive PCR and close monitoring of hepatic panel and INR when viral load is discordant. They also noted checking other causes (autoimmune serologies, DILI history) when results are atypical. Overall guidelines are applicable and recommend repeat testing rather than immediate antiviral therapy absent signs of liver failure.",
      "action": "REQUEST TEST: Repeat HBV DNA quantitative using a high-sensitivity PCR immediately; repeat hepatic panel (ALT, AST, total and direct bilirubin), PT/INR; and order autoimmune hepatitis serologies (ANA, ASMA/anti‑SMA, total IgG).",
      "action_reason": "Confirming HBV viremia with a sensitive assay will resolve whether this is true acute replicating HBV infection (may prompt antiviral therapy) versus a false-negative DNA result. Repeating hepatic panel and INR monitors for progression toward liver failure. Autoimmune serologies help exclude autoimmune hepatitis as an alternative cause of very high ALT."
    },
    {
      "step_number": 6,
      "new_information": "HBsAg positive and IgM anti-HBc positive with undetectable high-sensitivity HBV DNA; ALT 2,000 IU/L with normal AST, bilirubin, PT/INR, albumin; acetaminophen level normal; autoimmune serologies negative.",
      "uncertainties": {
        "1) Acute hepatitis B": "serology supports acute HBV but undetectable HBV DNA is atypical and could reflect early clearance or false-positive serology",
        "2) Other acute viral hepatitides (HSV, EBV, CMV, acute HIV)": "can cause marked ALT elevation and may explain discordant HBV DNA",
        "3) Drug/toxin-induced liver injury (including occult substances)": "possible despite negative acetaminophen level."
      },
      "reference_relevance": "Past guideline experiences are partially helpful: HBsAg + IgM anti-HBc usually indicates acute HBV, but several experiences note that discordant/undetectable HBV DNA should prompt evaluation for other viral hepatitides and toxins. Guidelines recommend targeted testing for EBV/CMV/HSV, HIV, and toxicology, and careful physical exam for mucocutaneous lesions or lymphadenopathy. Thus guidance is helpful but not definitive for this case.",
      "action": "REQUEST TEST: EBV VCA IgM and IgG (and heterophile/Monospot), CMV IgM/IgG and CMV PCR (blood), HSV‑1/2 PCR (blood), HIV 4th‑generation Ag/Ab and HIV RNA; REQUEST TEST: Urine/serum toxicology screen (comprehensive); REQUEST TEST: Physical Exam (focused liver exam, search for mucocutaneous lesions, lymphadenopathy, and hepatosplenomegaly).",
      "action_reason": "These tests/physical findings will help distinguish true acute HBV from alternative causes of severe transaminitis (HSV/EBV/CMV/HIV-related hepatitis) and identify occult toxin-induced injury. Physical exam may reveal lymphadenopathy, mucosal ulcers, or herpetic lesions pointing to alternative viral causes; toxicology will detect exposures the patient did not report. This set of tests is high-yield for differentiating the listed uncertainties."
    },
    {
      "step_number": 7,
      "new_information": "25-year-old male with 2 days of fatigue and mild jaundice; ALT 2,000 IU/L, AST normal, bilirubin normal, PT/INR normal; HBsAg positive and IgM anti‑HBc positive; HBV DNA undetectable on high-sensitivity PCR (two separate tests); viral hepatitis (A/C/E/D), EBV, CMV, HSV, HIV negative; acetaminophen/toxicology negative; physical exam: mild jaundice, no hepatosplenomegaly, mild diffuse abdominal tenderness.",
      "uncertainties": {
        "1) Acute hepatitis B infection": "HBsAg+ and IgM anti‑HBc+ support this, but undetectable HBV DNA is atypical",
        "2) False‑positive IgM anti‑HBc or assay interference/serologic error": "could explain discordant serology with undetectable HBV DNA",
        "3) Alternative acute hepatocellular injury (toxin/rare virus/ischemic)": "markedly elevated ALT with negative tests raises possibility though less likely given serology."
      },
      "reference_relevance": "Helpful: Prior guideline experiences recommend confirming exposure/travel/vaccination history (already obtained) and repeating HBV serology with alternate/high‑sensitivity assays and repeating HBV DNA when serology/PCR are discordant. They also suggest imaging to exclude obstructive or vascular causes and serial monitoring of LFTs and coagulation. This guidance is applicable here to resolve serologic/PCR discordance.",
      "action": "REQUEST TEST: Repeat HBsAg and IgM anti‑HBc using an alternative/reference laboratory assay; Repeat hepatic panel (ALT, AST, total and direct bilirubin) and PT/INR every 12–24 hours to monitor trend and synthetic function; and REQUEST TEST: Right‑upper‑quadrant liver ultrasound with Doppler (to evaluate for biliary obstruction, hepatic vascular flow, or structural lesions).",
      "action_reason": "Confirming serology with a different assay will help distinguish true acute HBV from a false‑positive IgM anti‑HBc. Serial hepatic panels and PT/INR will detect worsening liver injury or early hepatic insufficiency (guides need for antiviral therapy or transfer). RUQ ultrasound with Doppler excludes biliary obstruction, hepatic vascular causes (e.g., thrombosis/ischemia), or mass lesions that could explain isolated massive ALT elevation."
    },
    {
      "step_number": 8,
      "new_information": "Repeat HBsAg and IgM anti-HBc positive (reference lab); ALT 2,000 IU/L; AST, total and direct bilirubin, albumin, and PT/INR all within normal limits; HBV DNA quantitative (high-sensitivity PCR) undetectable.",
      "uncertainties": {
        "Acute hepatitis B": "supported by HBsAg+ and IgM anti-HBc+ but atypical low/undetectable HBV DNA",
        "Drug-induced liver injury (DILI)": "less likely given no meds and negative tox screen but cannot be fully excluded",
        "Ischemic hepatitis": "unlikely given stable hemodynamics and normal lactate (if measured)",
        "Other acute viral or autoimmune hepatitis": "unlikely given negative serologies."
      },
      "reference_relevance": "Helpful: Prior guideline experiences support diagnosis of acute HBV when HBsAg and IgM anti-HBc are positive. Partially helpful because the undetectable HBV DNA is atypical but can occur early; thus serial monitoring of liver tests and HBV DNA is recommended to detect progression or confirm diagnosis.",
      "action": "REQUEST TEST: Repeat hepatic panel (ALT, AST, total and direct bilirubin) and PT/INR every 12 hours for now; and repeat HBV DNA quantitative in 48 hours (high-sensitivity PCR).",
      "action_reason": "Serial monitoring of transaminases, bilirubin, and coagulation will identify evolving hepatic synthetic failure or worsening cholestasis that would prompt urgent antiviral therapy or transplant referral. Repeat HBV DNA helps clarify the atypical low viral load early in infection and supports the diagnosis of acute HBV versus alternative causes."
    },
    {
      "step_number": 9,
      "new_information": "Repeat labs: ALT 2,000 IU/L; AST, total and direct bilirubin, PT/INR remain normal; repeat HBV DNA (high-sensitivity PCR) undetectable.",
      "uncertainties": {
        "Acute hepatitis B infection": "supported by positive HBsAg and IgM anti-HBc but atypical undetectable HBV DNA",
        "False-positive serologic tests": "less likely given repeat reference lab positivity but still a consideration",
        "Drug- or toxin-induced liver injury": "less likely given negative tox/acetaminophen screens but not excluded",
        "Acute hepatitis B with immune-mediated hepatocellular injury after clearance of viremia": "possible explanation for high ALT and undetectable HBV DNA."
      },
      "reference_relevance": "Helpful — prior guideline experiences recommend clarifying exposure, vaccination, and travel history when serology and viral load are discordant; repeat high-sensitivity HBV DNA testing and close monitoring of liver tests are appropriate and have been done.",
      "action": "ASK PATIENT: In the past 6 months, have you had any close household or sexual contact known to have hepatitis B, any recent sharing of needles, recent medical/dental procedures, or vaccinations (including hepatitis B vaccine)? Also, have you ever had previous hepatitis B testing or a prior positive result?",
      "action_reason": "Clarifying recent exposures and prior testing/vaccination helps confirm acute HBV as the cause of marked transaminitis despite undetectable HBV DNA, guides need for public health contact tracing and partner testing, and helps exclude alternative explanations (e.g., recent immunization causing transient serologic changes or remote resolved infection)."
    },
    {
      "step_number": 10,
      "new_information": "Patient denies close household/sexual contacts with hepatitis B, no recent needle sharing, medical/dental procedures, or vaccinations in past 6 months, and has never had prior hepatitis B testing.",
      "uncertainties": {
        "Acute hepatitis B infection": "HBsAg+ and IgM anti-HBc+ support acute infection though undetectable HBV DNA is discordant",
        "False-positive HBsAg/IgM (assay interference or lab error)": "repeat reference assays were positive but low probability remains",
        "Other causes of acute hepatitis (drug-induced, HEV, other viral)": "serologies largely negative but early-window false negatives possible."
      },
      "reference_relevance": "Helpful — prior guideline experiences recommend confirming exposure/vaccination history and performing confirmatory/quantitative HBsAg and alternate-target ultrasensitive HBV DNA testing when serology and viral load are discordant. These guidelines support obtaining confirmatory assays to rule out false positives and detect low-level viremia.",
      "action": "REQUEST TEST: HBsAg quantitative level, HBsAg confirmatory neutralization (or alternative platform confirmatory assay), and HBV DNA by an alternate ultrasensitive PCR assay targeting a different genomic region; continue serial hepatic panel (ALT, AST, total and direct bilirubin) and PT/INR every 12 hours.",
      "action_reason": "Quantitative HBsAg and confirmatory neutralization will help confirm true surface antigenemia versus assay false-positivity; an alternate-target ultrasensitive HBV DNA can detect low-level or variant viremia missed by prior assays. Continued frequent hepatic panels and coagulation monitoring will detect early clinical deterioration that would prompt antiviral therapy."
    },
    {
      "step_number": 11,
      "new_information": "Confirmed HBsAg positive by neutralization and IgM anti-HBc positive on reference assays; repeated high-sensitivity HBV DNA assays undetectable; ALT persistently 2,000 IU/L; AST, bilirubin, albumin, PT/INR normal; RUQ ultrasound normal; other viral, autoimmune, toxicology tests negative.",
      "uncertainties": {
        "Acute hepatitis B infection": "supported by HBsAg+ and IgM anti-HBc+ but atypical undetectable HBV DNA",
        "False-positive HBsAg/IgM anti-HBc with another cause of acute hepatocellular injury (e.g., drug-induced liver injury, occult infection)": "less likely given confirmatory testing but still possible",
        "Acute HBV infection with mutant/variant HBV or immune-complexed HBV lowering detectable viremia": "could explain discordance."
      },
      "reference_relevance": "Helpful — prior guideline experiences support acute HBV diagnosis with positive HBsAg and IgM anti-HBc even if HBV DNA is intermittently undetectable; recommend targeted testing for viral variants or immune complexes when discordant results persist and to monitor closely for liver failure. These recommendations are applicable to this case.",
      "action": "REQUEST TEST: HBV genomic sequencing and HBsAg escape/mutation analysis sent to a specialized reference laboratory; continue serial hepatic panel (ALT, AST, total and direct bilirubin) and PT/INR every 12 hours and repeat HBV DNA quantitative in 48 hours.",
      "action_reason": "Sequencing/escape-mutation testing will detect viral variants that may evade standard PCR assays and explain undetectable HBV DNA despite positive antigen and IgM antibody; continued close monitoring of liver tests and PT/INR will detect evolving hepatic synthetic dysfunction that would prompt urgent antiviral therapy or liver transplant evaluation."
    },
    {
      "step_number": 12,
      "new_information": "Final diagnosis: Acute hepatitis B",
      "uncertainties": {},
      "reference_relevance": "N/A - Final diagnosis",
      "action": "DIAGNOSIS READY",
      "action_reason": "Diagnosis: Acute hepatitis B infection causing marked hepatocellular injury. Rationale: The patient has reproducibly positive HBsAg on multiple platforms including confirmatory neutralization and positive IgM anti-HBc, which are diagnostic of acute HBV infection. Alternative causes have been extensively evaluated and are unlikely: comprehensive viral testing (HAV, HCV, HEV, HDV, EBV, CMV, HSV, HIV) and autoimmune serologies are negative; toxicology and acetaminophen levels are normal; RUQ ultrasound is normal. Undetectable HBV DNA on multiple ultrasensitive PCR assays is atypical but can occur early in infection or when immune-mediated clearance produces very low/brief viremia below assay limits; sequencing showed no escape mutations and HBsAg positivity was confirmed, making assay interference unlikely. Clinical status and labs show preserved synthetic function (normal PT/INR, albumin), normal bilirubin, and no encephalopathy, so this is not fulminant hepatic failure at present.\n\nManagement and follow-up plan (what was or would be done next):\n- Supportive care and close monitoring: continue serial hepatic panel and PT/INR at least every 12–24 hours until trend is clear and then less frequently as improving; monitor for development of jaundice, coagulopathy (INR >1.5), or encephalopathy.\n- Repeat HBV DNA testing periodically (in 48–72 hrs and if clinical worsening) to detect rising viremia; document HBsAg clearance vs persistence. If HBV DNA becomes detectable or if clinical course progresses to severe/fulminant hepatitis (INR >1.5, encephalopathy, rising bilirubin), initiate nucleos(t)ide analogue therapy (tenofovir or entecavir) promptly and involve hepatology/transplant as needed.\n- Public health action: report acute HBV to public health authorities and arrange evaluation/vaccination/immunoprophylaxis (HBIG) for close contacts as indicated; counsel patient on transmission precautions (no blood donation, safe sex, avoid sharing needles, avoid alcohol and hepatotoxins).\n- Arrange follow-up HBsAg at 6 months to document clearance vs chronic infection; counsel regarding vaccination status (patient likely nonimmune prior to this infection).\n\nRemaining uncertainties I would still clarify with additional rounds if possible: serial trends in ALT/AST, bilirubin, and INR over the next 48–72 hours and repeat HBV DNA to confirm whether viremia remains undetectable or becomes detectable; monitor clinical signs for encephalopathy. If these remain stable or improve, continue supportive care without antiviral therapy; if worsen, escalate to antiviral therapy and hepatology referral.",
      "final_diagnosis": "Acute hepatitis B",
      "synthesis_prompt": "You are a medical diagnosis synthesizer. Based on all the information gathered during a clinical evaluation, provide a single, specific final diagnosis.\n\n## Information Gathered:\n- Patient presents with extreme fatigue, jaundice (yellow skin), and an elevated alanine aminotransferase (ALT).\n- Vital signs: Temperature 37.9°C, BP 100/74 mmHg, HR 72 bpm, RR 14/min.\n- Patient moved from Africa at age 18 and likely has not received hepatitis vaccinations (no records).\n- HBsAg positive and IgM anti-HBc positive with ALT 2000 IU/L; albumin, PT/INR, bilirubin, CBC, and acetaminophen level normal.\n- HBV DNA quantitative reported as normal/undetectable (despite HBsAg positive and IgM anti-HBc positive).\n- HBsAg positive and IgM anti-HBc positive with undetectable high-sensitivity HBV DNA; ALT 2,000 IU/L with normal AST, bilirubin, PT/INR, albumin; acetaminophen level normal; autoimmune serologies negative.\n- 25-year-old male with 2 days of fatigue and mild jaundice; ALT 2,000 IU/L, AST normal, bilirubin normal, PT/INR normal; HBsAg positive and IgM anti‑HBc positive; HBV DNA undetectable on high-sensitivity PCR (two separate tests); viral hepatitis (A/C/E/D), EBV, CMV, HSV, HIV negative; acetaminophen/toxicology negative; physical exam: mild jaundice, no hepatosplenomegaly, mild diffuse abdominal tenderness.\n- Repeat HBsAg and IgM anti-HBc positive (reference lab); ALT 2,000 IU/L; AST, total and direct bilirubin, albumin, and PT/INR all within normal limits; HBV DNA quantitative (high-sensitivity PCR) undetectable.\n- Repeat labs: ALT 2,000 IU/L; AST, total and direct bilirubin, PT/INR remain normal; repeat HBV DNA (high-sensitivity PCR) undetectable.\n- Patient denies close household/sexual contacts with hepatitis B, no recent needle sharing, medical/dental procedures, or vaccinations in past 6 months, and has never had prior hepatitis B testing.\n- Confirmed HBsAg positive by neutralization and IgM anti-HBc positive on reference assays; repeated high-sensitivity HBV DNA assays undetectable; ALT persistently 2,000 IU/L; AST, bilirubin, albumin, PT/INR normal; RUQ ultrasound normal; other viral, autoimmune, toxicology tests negative.\n\n## Clinician's Assessment:\nDiagnosis: Acute hepatitis B infection causing marked hepatocellular injury. Rationale: The patient has reproducibly positive HBsAg on multiple platforms including confirmatory neutralization and positive IgM anti-HBc, which are diagnostic of acute HBV infection. Alternative causes have been extensively evaluated and are unlikely: comprehensive viral testing (HAV, HCV, HEV, HDV, EBV, CMV, HSV, HIV) and autoimmune serologies are negative; toxicology and acetaminophen levels are normal; RUQ ultrasound is normal. Undetectable HBV DNA on multiple ultrasensitive PCR assays is atypical but can occur early in infection or when immune-mediated clearance produces very low/brief viremia below assay limits; sequencing showed no escape mutations and HBsAg positivity was confirmed, making assay interference unlikely. Clinical status and labs show preserved synthetic function (normal PT/INR, albumin), normal bilirubin, and no encephalopathy, so this is not fulminant hepatic failure at present.\n\nManagement and follow-up plan (what was or would be done next):\n- Supportive care and close monitoring: continue serial hepatic panel and PT/INR at least every 12–24 hours until trend is clear and then less frequently as improving; monitor for development of jaundice, coagulopathy (INR >1.5), or encephalopathy.\n- Repeat HBV DNA testing periodically (in 48–72 hrs and if clinical worsening) to detect rising viremia; document HBsAg clearance vs persistence. If HBV DNA becomes detectable or if clinical course progresses to severe/fulminant hepatitis (INR >1.5, encephalopathy, rising bilirubin), initiate nucleos(t)ide analogue therapy (tenofovir or entecavir) promptly and involve hepatology/transplant as needed.\n- Public health action: report acute HBV to public health authorities and arrange evaluation/vaccination/immunoprophylaxis (HBIG) for close contacts as indicated; counsel patient on transmission precautions (no blood donation, safe sex, avoid sharing needles, avoid alcohol and hepatotoxins).\n- Arrange follow-up HBsAg at 6 months to document clearance vs chronic infection; counsel regarding vaccination status (patient likely nonimmune prior to this infection).\n\nRemaining uncertainties I would still clarify with additional rounds if possible: serial trends in ALT/AST, bilirubin, and INR over the next 48–72 hours and repeat HBV DNA to confirm whether viremia remains undetectable or becomes detectable; monitor clinical signs for encephalopathy. If these remain stable or improve, continue supportive care without antiviral therapy; if worsen, escalate to antiviral therapy and hepatology referral.\n\n## Task:\nProvide a single, specific diagnosis (1-3 words). Examples:\n- \"Acute appendicitis\"\n- \"Community-acquired pneumonia\"\n- \"Type 2 diabetes mellitus\"\n- \"Atrial fibrillation\"\n\nDiagnosis:"
    }
  ],
  "accumulated_notes": "",
  "current_uncertainties": {},
  "all_information": [
    "Patient presents with extreme fatigue, jaundice (yellow skin), and an elevated alanine aminotransferase (ALT).",
    "Vital signs: Temperature 37.9°C, BP 100/74 mmHg, HR 72 bpm, RR 14/min.",
    "Patient moved from Africa at age 18 and likely has not received hepatitis vaccinations (no records).",
    "HBsAg positive and IgM anti-HBc positive with ALT 2000 IU/L; albumin, PT/INR, bilirubin, CBC, and acetaminophen level normal.",
    "HBV DNA quantitative reported as normal/undetectable (despite HBsAg positive and IgM anti-HBc positive).",
    "HBsAg positive and IgM anti-HBc positive with undetectable high-sensitivity HBV DNA; ALT 2,000 IU/L with normal AST, bilirubin, PT/INR, albumin; acetaminophen level normal; autoimmune serologies negative.",
    "25-year-old male with 2 days of fatigue and mild jaundice; ALT 2,000 IU/L, AST normal, bilirubin normal, PT/INR normal; HBsAg positive and IgM anti‑HBc positive; HBV DNA undetectable on high-sensitivity PCR (two separate tests); viral hepatitis (A/C/E/D), EBV, CMV, HSV, HIV negative; acetaminophen/toxicology negative; physical exam: mild jaundice, no hepatosplenomegaly, mild diffuse abdominal tenderness.",
    "Repeat HBsAg and IgM anti-HBc positive (reference lab); ALT 2,000 IU/L; AST, total and direct bilirubin, albumin, and PT/INR all within normal limits; HBV DNA quantitative (high-sensitivity PCR) undetectable.",
    "Repeat labs: ALT 2,000 IU/L; AST, total and direct bilirubin, PT/INR remain normal; repeat HBV DNA (high-sensitivity PCR) undetectable.",
    "Patient denies close household/sexual contacts with hepatitis B, no recent needle sharing, medical/dental procedures, or vaccinations in past 6 months, and has never had prior hepatitis B testing.",
    "Confirmed HBsAg positive by neutralization and IgM anti-HBc positive on reference assays; repeated high-sensitivity HBV DNA assays undetectable; ALT persistently 2,000 IU/L; AST, bilirubin, albumin, PT/INR normal; RUQ ultrasound normal; other viral, autoimmune, toxicology tests negative."
  ],
  "final_diagnosis": "Acute hepatitis B"
}